LivaNova PLC (NASDAQ:LIVN) Shares Sold by Bank of America Corp DE

Bank of America Corp DE lessened its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 16.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 491,089 shares of the company's stock after selling 94,006 shares during the period. Bank of America Corp DE owned approximately 0.90% of LivaNova worth $22,742,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. KBC Group NV lifted its holdings in shares of LivaNova by 130.5% during the 4th quarter. KBC Group NV now owns 99,928 shares of the company's stock valued at $4,628,000 after buying an additional 56,580 shares during the period. PNC Financial Services Group Inc. lifted its holdings in shares of LivaNova by 29.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock valued at $292,000 after buying an additional 1,424 shares during the period. Rhumbline Advisers lifted its holdings in shares of LivaNova by 0.5% during the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock valued at $8,240,000 after buying an additional 899 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in shares of LivaNova during the 4th quarter valued at $2,772,000. Finally, Envestnet Asset Management Inc. lifted its holdings in shares of LivaNova by 15.4% during the 4th quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock valued at $2,034,000 after buying an additional 5,850 shares during the period. Institutional investors own 97.64% of the company's stock.

LivaNova Price Performance

NASDAQ:LIVN traded down $1.30 on Friday, reaching $41.88. 602,740 shares of the company's stock traded hands, compared to its average volume of 651,153. The firm has a market cap of $2.28 billion, a PE ratio of 99.71 and a beta of 0.84. The stock has a 50-day simple moving average of $38.77 and a 200-day simple moving average of $44.60. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $61.94.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on LIVN shares. Robert W. Baird raised their target price on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price on the stock in a report on Tuesday. Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 target price on shares of LivaNova in a report on Tuesday, May 13th. Wall Street Zen cut LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. Finally, Mizuho decreased their price target on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, LivaNova currently has a consensus rating of "Buy" and a consensus target price of $59.29.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.